Shares of ImmuPharma plc (LON:IMM – Get Free Report) traded up 9.7% during trading on Friday . The company traded as high as GBX 4.50 ($0.06) and last traded at GBX 3.95 ($0.05). 24,599,076 shares traded hands during mid-day trading, an increase of 28% from the average session volume of 19,273,818 shares. The stock had previously closed at GBX 3.60 ($0.04).
ImmuPharma Stock Performance
The firm has a market capitalization of £16.39 million, a PE ratio of -393.60 and a beta of 1.53. The stock’s 50 day simple moving average is GBX 1.75 and its two-hundred day simple moving average is GBX 1.73.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Read More
- Five stocks we like better than ImmuPharma
- Where Do I Find 52-Week Highs and Lows?
- Bloom Energy: Powering the Future With Decentralized Energy
- Trading Stocks: RSI and Why it’s Useful
- Dividend Powerhouses: Blue-Chip Stocks Built for the Long Haul
- How to invest in marijuana stocks in 7 steps
- Why Traders Are Buying the Dip on Johnson & Johnson Stock
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
